Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3Phase 3 2Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 28Other hematologic neoplasm 24Lymphoid 17Breast 6Thoracic 3Gastrointestinal 3Dermatologic 2Classical hematology 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Pancreatic Neoplasms 2Colorectal Neoplasms 2Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × ruxolitinib × Gastrointestinal × Clear all
NCT02955940 2025-12-17

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Incyte Corporation

Phase 2 Active not recruiting
10 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02119676 2018-02-13

Study of Ruxolitinib in Colorectal Cancer Patients

Incyte Corporation

Phase 2 Terminated
396 enrolled 15 charts
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Colorectal Neoplasms

NCT01423604 2018-02-12

RECAP

Incyte Corporation

Phase 2 Completed
136 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡